Chlorpromazine tablets recalled over nitrosamine impurity above recommended intake limit
Major Pharmaceuticals is recalling 866 blister packs of Chlorpromazine Hydrochloride Tablets USP 100 mg because N-Nitroso Desmethyl Chlorpromazine was present above the recommended intake limit.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Scored 3 under the risk-of-harm criterion: a named nitrosamine impurity exceeding its recommended intake limit is a defined safety threshold breach, with no injuries reported.
Plain-English summary
Major ChlorproMAZINE Hydrochloride Tablets, USP, 100 mg, in 100-tablet (10x10) blister packages, packaged and distributed by Major Pharmaceuticals of Indianapolis, Indiana, are being recalled for CGMP deviations: the presence of N-Nitroso Desmethyl Chlorpromazine above the recommended intake limit.
The recall covers 866 blister packs carrying NDC 0904-7132-61, from lots N01920 (expiring 31 December 2025), N02023 (expiring 28 February 2026) and N02202 (expiring 30 June 2026). The product was distributed nationwide. The FDA has classified the recall as Class II.
The enforcement record identifies the nitrosamine impurity and the exceeded intake limit, and reports no injuries.
Chlorpromazine is a prescription medicine, so patients holding the affected lots should contact their pharmacy or prescriber about a replacement rather than stopping treatment on their own.
The recalled product
- Product
- Major ChlorproMAZINE Hydrochloride Tablets, USP, 100 mg, 100 Tablets (10x10) blister package, Rx Only, Packaged and Distributed by Major Pharmaceuticals, Indianapolis, IN 46268, USA, NDC 0904-7132-61, UPC (01)00309047132614
- Category
- Drug — Antipsychotic
- Affected units
- 866
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lots N01920
- Exp. Date
- 12/31/2025
- N02023
- 02/28/2026 & N02202
- 06/30/2026
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 5 recalled by The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
See all →- HighChlorpromazine 25 mg tablets recalled over nitrosamine above recommended intake limit
FDA (Drugs) · 2025-10-15
- HighChlorpromazine 25 mg fifty count packs recalled over nitrosamine impurity
FDA (Drugs) · 2025-10-15
- HighChlorpromazine 200 mg tablets recalled over nitrosamine above recommended intake limit
FDA (Drugs) · 2025-10-15
- HighChlorpromazine 50 mg tablets recalled over nitrosamine above recommended intake limit
FDA (Drugs) · 2025-10-15
- ModerateCardinal Health antibiotic tablets recalled over micro-organism on packaging coil
FDA (Drugs) · 2025-09-17
Same hazard · nitrosamine
See all →- SevereFDA Recalls Mirabegron Tablets Over Nitrosamine Impurity
FDA (Drugs) · 2026-08-12
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over a nitrosamine impurity
FDA (Drugs) · 2026-02-11
- HighClomipramine 25 mg capsules recalled over nitrosamine above the intake limit
FDA (Drugs) · 2025-11-12